Company / R&D Expense
Biohaven Ltd. R&D Expense History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$795.9M
FY2024
5-year range
$98.5M / $795.9M
FY2020-FY2024
Trend
+113.2%
vs FY2023
Sector context
#23 of 210
Health Care
What the data says
Biohaven Ltd.'s r&d expense of $796M is higher than 89% of companies in the Health Care sector (FY2024). Improved from $437M to $796M over the past 2 years.
Based on SEC 10-K filings.
$796M in FY2024 with a 3-year CAGR of +63.7%. Top quartile in the Health Care sector.
Improved from $437M to $796M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +63.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 11% in Health CareTop 11% of 210This company $795.9M Sector average $644.0M
▼
+23.6% above sector average
Key checks
Key Insights
- 3-year CAGR of +63.7%, indicating consistent growth.
- In FY2024, r&d expense increased 113.2% year-over-year.
- Ranks #23 out of 210 companies in the Health Care sector.
- Lowest r&d expense in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.10 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $795.9M | +113.2% |
| FY2023 | $373.3M | -14.6% |
| FY2022 | $437.1M | +140.8% |
| FY2021 | $181.5M | +84.3% |
| FY2020 | $98.5M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026